Clinical trials: Sitagliptin, completed
Heart Failure With Reduced Ejection Fraction, Chronic Heart Failure
Emulation of the EMPEROR-Reduced Trial Using Healthcare Claims Data
Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials.
- Trial name
- NCT07599345
- Testing
- Empagliflozin, Sitagliptin
- Where
- United States
- Volunteers
- 23,955 people
- Sponsor
- Brigham and Women's Hospital
Diabete Mellitus, Type 2 Diabetes
Mangosteen Supplement as Adjuvant Therapy With Sitagliptin/Metformin in Iraqi Patients With Type 2 Diabetes
This clinical trial was conducted at the National Diabetes Center for Treatment and Research, Mustansiriyah University, Baghdad (Sept 2024-May 2025).
- Conditions
- Diabete Mellitus, Type 2 Diabetes, Obesity Type 2 Diabetes Mellitus, Dyslipidemia in Patients With Diabetes Mellitus
- Trial name
- NCT07172269
- Testing
- Sitagliptin + Metformin, mangosteen supplement, Lifestyle Management
- Where
- Iraq
- Volunteers
- 58 people
- Sponsor
- Mais Qais Hbeeb
Type 2 Diabetes Mellitus
24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years
The purpose of this study is to evaluate benefits and risks of lixisenatide (AVE0010), in comparison to sitagliptin, as an add-on treatment to metformin, in obese (body mass index [BMI] greater than or equal to 30 kilogram per…
- Trial name
- NCT00976937
- Testing
- Lixisenatide (AVE0010), Pen auto-injector, Sitagliptin
- Where
- 92 sites in United States, Australia and 11 more
- Volunteers
- 319 people
- Sponsor
- Sanofi
Healthy Subjects
Bioequivalence of Sitagliptin Phosphate/Metformin Hydrochloride Tablets in Healthy Chinese Subjects
An open-label, randomized, single-dose, two-period, two-group, crossover study was conducted in 48 healthy Chinese volunteers under fasted or fed conditions (24 volunteers for each condition) to assess the bioequivalence between…
- Trial name
- NCT04877106
- Testing
- Sitagliptin Phosphate/metformin Hydrochloride Tablets(JANUMET®,50mg/850mg), Sitagliptin Phosphate/metformin Hydrochloride Tablets (50mg/850mg)
- Where
- China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- The Affiliated Hospital of Qingdao University
Posttransplant Diabetes Mellitus
Efficacy Study of Sitagliptin to Prevent New-onset Diabetes After Kidney Transplant
The purpose of this study is to determine whether sitagliptin is effective in preventing the development of new-onset diabetes after kidney transplant (NODAT).
- Trial name
- NCT01928199
- Testing
- Sitagliptin
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Washington University School of Medicine
Type 2 Diabetes Mellitus
An Observational Study of Type II Diabetics Treated With Dual Therapy With or Without Sitagliptin (Januvia®/Xelevia®, MK-0431-201)
This is an observational study to compare the effectiveness of dual therapy of Type II diabetes mellitus with metformin + sitagliptin versus metformin + a sulfonylurea in routine clinical practice in France.
- Trial name
- NCT01357135
- Testing
- Metformin, Sitagliptin, Sulfonylurea
- Volunteers
- 3,453 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes, Diabetes Mellitus, Type 2
Effect of Detemir and Sitagliptin on Blood Glucose Control in Type 2 Diabetes
This trial is conducted in Asia, Europe and North America. This trial aims for comparison of the effect on the glycemic control in subjects with type 2 diabetes of basal insulin analogue with one oral anti-diabetic drug (OAD)…
- Trial name
- NCT00789191
- Testing
- insulin detemir, sitagliptin, metformin
- Where
- 51 sites in United States, Canada and 6 more
- Volunteers
- 222 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2, Urosepsis
Safety of Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors Among Patients With Type 2 Diabetes
The purpose of this study is to compare the risk of serious adverse events associated with the use of sodium-glucose cotransporter 2 (SGLT2) inhibitors in comparison with the use of dipeptidyl peptidase-4 (DPP-4) inhibitors among…
- Conditions
- Diabetes Mellitus, Type 2, Urosepsis, Diabetic Ketoacidosis, Lower Extremity Amputation
- Trial name
- NCT04017221
- Testing
- Sodium-glucose cotransporter 2 (SGLT2) inhibitors, Dipeptidyl peptidase-4 (DPP-4) inhibitors, Other treatment combinations
- Where
- Canada
- Volunteers
- 1,249,636 people
- Sponsor
- Canadian Network for Observational Drug Effect Studies, CNODES
Type 2 Diabetes
The INDORSE Study: Inhibition of Dipeptidyl Peptidase IV: Outcomes on Renal Sodium Excretion
Background: Dedicated renal hemodynamic and renal function studies are lacking for DPP-4 inhibitors in patients with Type 2 diabetes; accordingly little is known regarding the mechanisms mediating the renal effects of DPP-4…
- Trial name
- INDORSE (NCT02406443)
- Testing
- Sitaglitpin
- Where
- Canada
- Volunteers
- 36 people
- Sponsor
- University Health Network, Toronto
Gastroparesis, Diabetes Mellitus
Effects of Sitagliptin on Gastric Emptying, Glycaemia and Blood Pressure in Type 2 Diabetes
The purpose of this study is to evaluate the acute effects of sitagliptin on postprandial glycemia, incretin hormones and blood pressure, and the relationship to gastric emptying, after a mashed potato meal in patients with type…
- Trial name
- NCT02324010
- Testing
- Sitagliptin
- Where
- Australia
- Volunteers
- 14 people
- Sponsor
- Royal Adelaide Hospital
Diabetes Mellitus, Type 2
An Efficacy Study of Canagliflozin or Sitagliptin to Determine Glucose Variability in Mexican Participants With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin
The main purpose of this study is to assess the effects of 4 weeks each of daily treatment with canagliflozin 300 milligram (mg) versus sitagliptin 100 mg as treatment adjuncts to metformin (at stable dosages) on intrapatient…
- Trial name
- COMETA (NCT03267576)
- Testing
- Canagliflozin 300 mg, Sitagliptin 100 mg, Metformin
- Where
- 5 sites in Mexico
- Volunteers
- 64 people
- Sponsor
- Janssen Research & Development, LLC
Bioequivalance
Clinical Study to Determine Bioequivalence Between Two Oral Medications of Sitagliptin/Metformin in Prolonged-release Tablets With 100 mg/1000 mg in Healthy Subjects, Fed Study.
Prospective, longitudinal, single-dose, randomized, open-label, crossover 2x2, two treatments, two periods, two sequences controlled clinical study
- Trial name
- ACL25-IC005 (NCT07763964)
- Testing
- Janumet XR, Sitagliptin/Metformin FDC
- Where
- Mexico
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- ADIUM
Type 2 Diabetes Mellitus
Sitagliptin Added-on to Insulin Study (0431-051)
A clinical study to determine the safety and efficacy of sitagliptin in patients with Type 2 Diabetes Mellitus who have inadequate glycemic control on insulin or insulin/metformin combination therapy.
- Trial name
- NCT00395343
- Testing
- sitagliptin phosphate
- Volunteers
- 641 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
BI 10773 add-on to Metformin in Patients With Type 2 Diabetes
The objective of the current study is to investigate the efficacy, safety and pharmacokinetics of five doses of BI 10773 compared to placebo given for 12 weeks as add-on therapy to on going metformin therapy in patients with T2DM…
- Trial name
- NCT00749190
- Testing
- BI 10773, sitagliptin
- Where
- 116 sites in United States, Argentina and 14 more
- Volunteers
- 495 people
- Sponsor
- Boehringer Ingelheim
Liver Insufficiency
A Study of MK0431 in Patients WIth Hepatic Insufficiency (0431-017)(COMPLETED)
A study to compare the plasma concentrations of MK0431 at different times in patients with hepatic insufficiency vs healthy control subjects.
- Trial name
- NCT00696826
- Testing
- sitagliptin phosphate
- Volunteers
- 20 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
Study to Evaluate the Efficacy of Acarbose,Metformin,Sitagliptin Combination Treatment in DM Patients
Primary objective To evaluate the efficacy of Acarbose add-on therapy on glucose control in subjects with type 2 diabetes inadequately controlled with Metformin and Sitagliptin combination therapy.
- Trial name
- NCT01490918
- Testing
- Acarbose
- Where
- South Korea
- Volunteers
- 165 people
- Sponsor
- The Catholic University of Korea
Diabetes Mellitus, Type 2
Glucagon-like Peptide (GLP) Utilization and Safety
This study will assess the utilization patterns (adherence, source of the index antidiabetic agent (ADA) and treatment modification) of the marketed glucagon-like peptide-1 (GLP-1) receptor agonists (exenatide and liraglutide)…
- Trial name
- NCT01767389
- Testing
- The GLP-1 receptor agonist users, DPP-4 inhibitor users, Other ADA users
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes Mellitus
A Study to Test the Safety and Efficacy of Adding Sitagliptin in Patients With Type 2 Diabetes Mellitus (MK0431-074)
A study to assess the safety and efficacy of the addition of sitagliptin compared to placebo in patients with Type 2 Diabetes Mellitus who have inadequate glycemic control on metformin.
- Trial name
- NCT00813995
- Testing
- Comparator: Sitagliptin phosphate
- Volunteers
- 395 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
Doxycycline in Type II Diabetes
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease characterized by hyperglycemia, weight loss, and cardio-metabolic complications.
- Trial name
- NCT06329882
- Testing
- Sitagliptin 100mg, Doxycyclin
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Mostafa Bahaa
Diabetes Mellitus, Type 2
Superiority of Glimepiride Over Sitagliptin in Naive Type 2 Diabetes Patients
Primary Objective: To determine the superiority of glimepiride over sitagliptin in the reduction of HbA1c after 6 months of treatment in patients with monotherapy until the end of the trial.
- Trial name
- SUMER (NCT00957060)
- Testing
- GLIMEPIRIDE (HOE490), SITAGLIPTIN
- Where
- 2 sites in Guatemala, Mexico
- Volunteers
- 400 people
- Sponsor
- Sanofi